ECSP077223A - Indazoles utiles en el tratamiento de enfermedades cardiovasculares - Google Patents
Indazoles utiles en el tratamiento de enfermedades cardiovascularesInfo
- Publication number
- ECSP077223A ECSP077223A EC2007007223A ECSP077223A ECSP077223A EC SP077223 A ECSP077223 A EC SP077223A EC 2007007223 A EC2007007223 A EC 2007007223A EC SP077223 A ECSP077223 A EC SP077223A EC SP077223 A ECSP077223 A EC SP077223A
- Authority
- EC
- Ecuador
- Prior art keywords
- useful
- treatment
- indazols
- cardiovascular diseases
- lxr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Abstract
Esta invención proporciona compuestos de la Fórmula (I) o (Ia):que son útiles en el tratamiento o inhibición de enfermedades mediadas por LXR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59857304P | 2004-08-03 | 2004-08-03 | |
US66973705P | 2005-04-08 | 2005-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP077223A true ECSP077223A (es) | 2007-03-29 |
Family
ID=35311622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2007007223A ECSP077223A (es) | 2004-08-03 | 2007-02-02 | Indazoles utiles en el tratamiento de enfermedades cardiovasculares |
Country Status (21)
Country | Link |
---|---|
US (1) | US7592363B2 (es) |
EP (2) | EP2295429A1 (es) |
JP (1) | JP2008509138A (es) |
KR (1) | KR20070045226A (es) |
CN (1) | CN101213194A (es) |
AR (1) | AR050279A1 (es) |
AU (1) | AU2005271737A1 (es) |
BR (1) | BRPI0514017A (es) |
CA (1) | CA2575180A1 (es) |
CR (1) | CR8888A (es) |
EC (1) | ECSP077223A (es) |
GT (1) | GT200500208A (es) |
IL (1) | IL180759A0 (es) |
MX (1) | MX2007000791A (es) |
NO (1) | NO20070933L (es) |
PA (1) | PA8640701A1 (es) |
PE (1) | PE20060417A1 (es) |
RU (1) | RU2007101488A (es) |
SV (1) | SV2006002187A (es) |
TW (1) | TW200605886A (es) |
WO (1) | WO2006017384A2 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3658525A (en) * | 1970-12-03 | 1972-04-25 | Eastman Kodak Co | Reversal color photographic processes |
TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
ES2438739T3 (es) | 2005-06-28 | 2014-01-20 | Daiichi Sankyo Company, Limited | Procedimiento de prueba de ligando LXR |
BRPI0716833A2 (pt) * | 2006-09-19 | 2013-11-05 | Wyeth Corp | Uso de agonistas de lxr para o tratamento de osteoartrite |
US20080070883A1 (en) * | 2006-09-19 | 2008-03-20 | Wyeth | Use of LXR modulators for the prevention and treatment of skin aging |
ITMI20062230A1 (it) * | 2006-11-22 | 2008-05-23 | Acraf | Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende |
EP2128138A1 (en) * | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
CA2677264C (en) | 2007-02-02 | 2021-11-30 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
CA2687754C (en) * | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
AU2008258549B2 (en) | 2007-06-08 | 2013-11-14 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
WO2008148851A1 (en) * | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) * | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
CA2710454A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth Llc | Pyrazolo [1,5-a] pyrimidine compounds |
CA2710458A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth Llc | Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors |
WO2009102789A2 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteroarthritis |
WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
CA2782601C (en) | 2009-12-18 | 2015-07-21 | Mitsubishi Tanabe Pharma Corporation | Novel antiplatelet agent |
EP2600864B1 (en) * | 2010-08-04 | 2019-01-09 | University Of Virginia Patent Foundation | Compositions and methods for treating inflammatory diseases |
CA2811145A1 (en) | 2010-09-07 | 2012-03-15 | Snu R&Db Foundation | Sesterterpene compound and use thereof |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
WO2012139495A1 (en) * | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
JP5959330B2 (ja) * | 2011-06-17 | 2016-08-02 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
ES2702237T3 (es) * | 2011-12-21 | 2019-02-28 | Allergan Inc | Compuestos que actúan en receptores de prostaglandina múltiples que dan una respuesta antiinflamatoria general |
HUE040231T2 (hu) | 2012-03-02 | 2019-02-28 | Ralexar Therapeutics Inc | Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére |
WO2014026328A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
CN104151300B (zh) * | 2013-05-15 | 2018-07-13 | 中国医学科学院医药生物技术研究所 | 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途 |
ES2804304T3 (es) | 2013-09-04 | 2021-02-05 | Ellora Therapeutics Inc | Moduladores del receptor X hepático (LXR) |
CA2923178A1 (en) | 2013-09-04 | 2015-03-12 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
WO2015089218A1 (en) * | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
WO2015109285A1 (en) | 2014-01-20 | 2015-07-23 | Cleave Biosciences, Inc. | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX |
WO2016057454A1 (en) | 2014-10-06 | 2016-04-14 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
JP2018510135A (ja) | 2015-02-11 | 2018-04-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害剤としての置換ピラゾール化合物及びその使用 |
CN105331647B (zh) * | 2015-07-03 | 2019-02-22 | 赣南师范大学 | 一种微生物体内合成脂肪醇乙酸酯的方法 |
CN105153125A (zh) * | 2015-09-29 | 2015-12-16 | 青岛友诚高新技术有限公司 | 一种可用于制备保护心肌缺血药物的化合物及其制备方法、用途 |
EP3368539B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as ror gamma t inhibitors and uses thereof |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
WO2017075178A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
EP3402477A4 (en) | 2016-01-11 | 2019-08-21 | The Rockefeller University | METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS |
US11274092B2 (en) * | 2016-02-24 | 2022-03-15 | Acesion Pharma Aps | Potassium channel inhibitors |
WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
MA54296A (fr) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc | Procédés de traitement du métabolisme lipidique dérégulé |
UY38721A (es) * | 2019-05-31 | 2020-11-30 | Janssen Pharmaceutica Nv | INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB |
EP3999055A1 (en) | 2019-07-15 | 2022-05-25 | Novartis AG | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
WO2021022061A1 (en) * | 2019-07-30 | 2021-02-04 | Oregon State University | Aryl hydrocarbon receptor activators |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152135A (en) | 1962-11-02 | 1964-10-06 | Warner Lambert Pharmaceutical | Heterocyclic substituted indazole compounds and process therefor |
US3541110A (en) | 1967-01-20 | 1970-11-17 | American Home Prod | Indazole-5-sulfonamides |
IL84944A (en) | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
US5321028A (en) * | 1988-09-02 | 1994-06-14 | Janssen Pharmaceutica N.V. | Antihypertensive 3-piperidinyl-indazole derivatives |
FR2673628B1 (fr) | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
JPH04282372A (ja) | 1991-03-08 | 1992-10-07 | Nissan Chem Ind Ltd | インダゾール誘導体の製造方法 |
US6005109A (en) | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
JPH0717950A (ja) | 1993-06-29 | 1995-01-20 | Fuji Photo Film Co Ltd | アゾ化合物の製造方法と得られたアゾ化合物を用いたインダゾールの製造方法 |
DE19612291A1 (de) | 1996-03-28 | 1997-10-02 | Bernhard K Prof Dr Dr Keppler | Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe |
DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
KR100630530B1 (ko) | 1997-10-24 | 2006-09-29 | 닛산 가가쿠 고교 가부시키 가이샤 | 술파모일 화합물 및 농원예용 살균제 |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
WO2000063207A1 (en) | 1999-04-20 | 2000-10-26 | Syngenta Limited | Pesticidal indazole or benzotriazole derivatives |
RU2002110295A (ru) | 1999-09-17 | 2003-12-10 | Милленниум Фармасьютикалс, Инк. (Us) | Ингибиторы фактора Ха |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
WO2002016348A1 (en) | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
DE10046029A1 (de) | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
US7101884B2 (en) * | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US20030109550A1 (en) | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
JP5039268B2 (ja) * | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
BR0316950A (pt) | 2002-12-02 | 2006-01-17 | Hoffmann La Roche | Derivados de indazol como antagonistas de crf |
RU2376292C2 (ru) * | 2003-08-14 | 2009-12-20 | Ф.Хоффманн-Ля Рош Аг | Гамк-ергические модуляторы |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
-
2005
- 2005-08-01 MX MX2007000791A patent/MX2007000791A/es active IP Right Grant
- 2005-08-01 GT GT200500208A patent/GT200500208A/es unknown
- 2005-08-01 CN CNA2005800309245A patent/CN101213194A/zh active Pending
- 2005-08-01 PE PE2005000888A patent/PE20060417A1/es not_active Application Discontinuation
- 2005-08-01 US US11/194,263 patent/US7592363B2/en not_active Expired - Fee Related
- 2005-08-01 JP JP2007524862A patent/JP2008509138A/ja active Pending
- 2005-08-01 PA PA20058640701A patent/PA8640701A1/es unknown
- 2005-08-01 EP EP10177298A patent/EP2295429A1/en not_active Withdrawn
- 2005-08-01 WO PCT/US2005/026970 patent/WO2006017384A2/en active Application Filing
- 2005-08-01 TW TW094125997A patent/TW200605886A/zh unknown
- 2005-08-01 KR KR1020077002741A patent/KR20070045226A/ko not_active Application Discontinuation
- 2005-08-01 EP EP05777241A patent/EP1773781A2/en not_active Withdrawn
- 2005-08-01 RU RU2007101488/04A patent/RU2007101488A/ru not_active Application Discontinuation
- 2005-08-01 BR BRPI0514017-0A patent/BRPI0514017A/pt not_active IP Right Cessation
- 2005-08-01 AU AU2005271737A patent/AU2005271737A1/en not_active Abandoned
- 2005-08-01 CA CA002575180A patent/CA2575180A1/en not_active Abandoned
- 2005-08-01 AR ARP050103205A patent/AR050279A1/es not_active Application Discontinuation
- 2005-08-08 SV SV2005002187A patent/SV2006002187A/es not_active Application Discontinuation
-
2007
- 2007-01-17 IL IL180759A patent/IL180759A0/en unknown
- 2007-02-01 CR CR8888A patent/CR8888A/es not_active Application Discontinuation
- 2007-02-02 EC EC2007007223A patent/ECSP077223A/es unknown
- 2007-02-19 NO NO20070933A patent/NO20070933L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2575180A1 (en) | 2006-02-16 |
NO20070933L (no) | 2007-03-28 |
BRPI0514017A (pt) | 2008-05-27 |
WO2006017384A3 (en) | 2007-09-20 |
GT200500208A (es) | 2006-03-02 |
PE20060417A1 (es) | 2006-06-13 |
EP2295429A1 (en) | 2011-03-16 |
MX2007000791A (es) | 2007-03-23 |
TW200605886A (en) | 2006-02-16 |
AR050279A1 (es) | 2006-10-11 |
JP2008509138A (ja) | 2008-03-27 |
PA8640701A1 (es) | 2006-09-08 |
CN101213194A (zh) | 2008-07-02 |
CR8888A (es) | 2007-08-28 |
AU2005271737A1 (en) | 2006-02-16 |
US20060030612A1 (en) | 2006-02-09 |
SV2006002187A (es) | 2006-09-14 |
WO2006017384A2 (en) | 2006-02-16 |
US7592363B2 (en) | 2009-09-22 |
KR20070045226A (ko) | 2007-05-02 |
EP1773781A2 (en) | 2007-04-18 |
IL180759A0 (en) | 2007-06-03 |
RU2007101488A (ru) | 2008-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP077223A (es) | Indazoles utiles en el tratamiento de enfermedades cardiovasculares | |
CR8410A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares | |
ECSP077360A (es) | Compuestos sulfonamida | |
DK1853602T3 (da) | Kemiske forbindelser | |
DK1853588T3 (da) | Kemiske forbindelser | |
CY1118523T1 (el) | Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus | |
NO20084502L (no) | Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer | |
ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
ECSP066717A (es) | Compuestos de quinolina sustituidos | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
EA200501771A1 (ru) | Лиганды каннабиноидных рецепторов и их применения | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
GT200600013A (es) | Compuestos organicos | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
NO20083011L (no) | Modulatorer av muskarine receptorer | |
EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
HN2010000313A (es) | Pirimidinas biciclicas fusionadas | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
SV2006002001A (es) | Inhibidores de quinasa ref. x - 16437 | |
CO6382123A2 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения | |
CY1114807T1 (el) | Ενωσεις 2,4-πυριμιδινοδιαμινης για τη θεραπευτικη αντιμετωπιση ή την προληψη αυτοανοσων νοσων | |
DOP2005000015A (es) | Compuestos de quinolina sustituidos | |
DOP2006000256A (es) | Compuestos de pirimidinil benzotiofeno |